Page 78 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $2.40
52wk Low $1.12 Dyadic International, Inc. DYAI $1.87
1044 North U.S. Highway One
Jupiter, FL 33477-5094

(USD - in millions) www.dyadic.com
Market Cap 52.1
Enterprise 44.1
Basic Shares Out. 28.81 COMPANY OVERVIEW
Float 18.70
Institutional Holdings 10.15% Detailed Analysis:Channelchek.com
Short Interest 0.18
Avg. 90-Day Volume 0.02 Dyadic International, Inc. is a global biotechnology company which is
developing what it believes will be a potentially significant
biopharmaceutical gene expression platform based on the industrially
proven hyper productive engineered fungus Thermothelomyces
EPS Data heterothallica (formerly Myceliophthora thermophila), named C1. The
C1 microorganism, which enables the development and large scale
2021 2022 2023 manufacture of low cost proteins, has the potential to be further
CQ1 N/A (0.09) (0.03) developed into a safe and efficient expression system that may help
CQ2 (0.14) (0.12) (0.07) speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
CQ3 (0.06) (0.06) (0.06) scales.
CQ4 (0.15) (0.07) (0.07)
CY (0.47) (0.34) (0.23) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.27
ROE (ttm) -67.80
Debt-to-Total Cap. (mrq) 1.90
Fiscal Year End 31-Dec
J
1044 North U. upiter FL 33477-5094

Key Executives
CEO: Emalfarb, Mark
CFO: Rawson, Ping
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures